NIH cancer chief to serve as acting FDA commissioner
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 12/03/2019 (2757 days ago), so information in it may no longer be current.
WASHINGTON – The head of the National Cancer Institute will temporarily take charge of the Food and Drug Administration next month after the departure of its current chief.
The appointment Tuesday of Dr. Ned Sharpless comes a week after Scott Gottlieb unexpectedly announced his resignation.
Sharpless currently heads the National Institutes of Health’s cancer division, which directs billions in federal funding and grants for research. His name has been circulated as one of several government officials likely to succeed Gottlieb on a permanent basis.
Health and Human Services Secretary Alex Azar said the search for a new FDA commissioner is underway.
The FDA’s top official is nominated by the president and must be confirmed by the Senate, typically following public hearings before health lawmakers.
Last Tuesday, Gottlieb said he would step in down in April after less than two years leading the FDA, a massive public health agency that regulates the food, drug, medical device and tobacco industries, among others. He was widely viewed as one of President Donald Trump’s most effective administrators, serving as a key messenger on the federal response to rising drug prices, the opioid epidemic and underage use of e-cigarettes.
Gottlieb said he wants to spend more time with his family after commuting weekly to Washington from his home in Connecticut.
During his tenure, Gottlieb launched a series of ambitious public health initiatives, including a plan to make cigarettes less addictive by drastically cutting nicotine levels. But that plan and many others have barely progressed beyond the earliest stages, raising questions about their timeline and prospects for completion. FDA commissioners report to the White House, but generally have broad leeway to choose their priorities.
Sharpless has publicly supported FDA’s efforts to more tightly regulate tobacco and crack down on underage vaping. E-cigarettes are generally viewed as less harmful than traditional tobacco products, but they usually contain nicotine which can harm the adolescent brain. Some research also suggests that teenagers who use e-cigarettes are more likely to try regular cigarettes.
Sharpless has led the National Cancer Institute since October 2017. He previously was a professor and administrator at the University of North Carolina, where he also earned his medical degree in 1993.
___
The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
